Convulsive Status Epilepticus (CSE) is the most common childhood neurological emergency, sometimes resulting in death or serious disability. CSE is managed with anticonvulsant medications in a step-wise approach until seizures stop. While some management strategies for CSE are well supported by evidence (e.g. initial administration of benzodiazepines), subsequent strategies are based on expert consensus and not evidence.
Phenytoin, the traditional second line agent for CSE has a high failure rate, causes adverse events and must be administered slowly. Levetiracetam, a newer anticonvulsant, has a favourable adverse events profile, can be administered quickly and has good efficacy for various seizure types.
This research project proposes to undertake a randomised controlled trial of the second line anticonvulsants phenytoin and levetiracetam for CSE in children. This multi-centre study will be a world first and have a profound impact on the management of CSE in children in New Zealand, Australia and worldwide, in either confirming the current second line medication used or recommending a newer second line medication.
- $77,523.16 Private Practice Trust Funding
- Dalziel S. R., Furyk J., Bonisch M., Oakley E., Borland M., Neutze J., Donath S., Sharpe C., Harvey S., Davidson A., Craig S., Phillips N., George S., Rao A., Cheng N., Zhang M., Sinn K., Kochar A., Brabyn C., Babl F.E., “A multicentre randomised controlled trial of levetiracetam versus phenytoin for convulsive status epilepticus in children (protocol): Convulsive Status Epilepticus Paediatric Trial (ConSEPT) - a PREDICT study”, 'BMC Pediatrics', 2017;17(1):152. doi:10.1186/s12887-017-0887-8
Dr Jeremy Furyk
Dr Natalie Phillips
Dr Shane George
Ms Jenine Lawlor
A/Prof Ed Oakley
A/Prof Franz Babl
Dr Stuart Dalziel